Document is current
Any future updates will be listed below
-
Authors
Ruder, Sundeep
Mansfield, Brett
Immelman, Andrew Ronald
Varki, Nissi
Miu, Phuong
Raal, Frederick
Tsimikas, Sotirios
-
Funding
Funding for this research was provided by:
NHLBI (HL159156)
- License Information
-
More Information
Article History
Received: 15 September 2022
Accepted: 6 October 2022
First Online: 1 November 2022
Declarations
:
: The study was by the ethics committee of the University of the Witwatersrand.
: All authors contributed significantly to the manuscript for intellectual content and provided consent for publication.
: ST is a co-inventor and receives royalties from patents owned by UCSD on oxidation-specific antibodies and of biomarkers related to oxidized lipoproteins, is a co-founder and has an equity interest in Oxitope, Inc and its affiliates (“Oxitope”), Kleanthi Diagnostics, LLC (“Kleanthi”) and Covicept Therapeutics. Although these relationships have been identified for conflict of interest management based on the overall scope of the project and its potential benefit to Oxitope and Kleanthi, the research findings included in this particular publication may not necessarily relate to the interests of Oxitope and Kleanthi. The terms of this arrangement have been reviewed and approved by the University of California, San Diego in accordance with its conflict of interest policies. The other authors have no conflicts.
